MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

REVOLUTION Medicines Inc

Geschlossen

BrancheGesundheitswesen

37.9 -1.3

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

37.76

Max

38.43

Schlüsselkennzahlen

By Trading Economics

Einkommen

-19M

-213M

EPS

-1.13

Gewinnspanne

-74.379

Angestellte

616

EBITDA

-24M

-237M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+84.1% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-754M

6.8B

Vorheriger Eröffnungskurs

39.2

Vorheriger Schlusskurs

37.9

Nachrichtenstimmung

By Acuity

50%

50%

174 / 376 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

REVOLUTION Medicines Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

11. Juli 2025, 22:19 UTC

Akquisitionen, Fusionen, Übernahmen

FCC Approves U.S. Cellular Sale to T-Mobile

11. Juli 2025, 17:28 UTC

Wichtige Markttreiber

SharpLink Gaming Gains on Ethereum Purchase

11. Juli 2025, 16:57 UTC

Ergebnisse

BASF Cuts Outlook on Global Economy Uncertainty

11. Juli 2025, 21:45 UTC

Market Talk

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11. Juli 2025, 19:46 UTC

Akquisitionen, Fusionen, Übernahmen

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11. Juli 2025, 19:45 UTC

Market Talk

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11. Juli 2025, 19:05 UTC

Market Talk

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11. Juli 2025, 18:18 UTC

Market Talk

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11. Juli 2025, 17:35 UTC

Market Talk

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11. Juli 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11. Juli 2025, 16:53 UTC

Market Talk

Crude Futures Add to Early Gains -- Market Talk

11. Juli 2025, 16:42 UTC

Ergebnisse

BASF Cuts Outlook on Global Economic Uncertainty

11. Juli 2025, 16:08 UTC

Market Talk

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11. Juli 2025, 16:05 UTC

Ergebnisse

BASF Will Publish Half-Year Results on July 30

11. Juli 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

11. Juli 2025, 16:04 UTC

Market Talk

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11. Juli 2025, 16:03 UTC

Ergebnisse

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11. Juli 2025, 16:02 UTC

Ergebnisse

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11. Juli 2025, 16:01 UTC

Ergebnisse

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11. Juli 2025, 16:00 UTC

Ergebnisse

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11. Juli 2025, 15:59 UTC

Ergebnisse

BASF Cuts 2025 Earnings View

11. Juli 2025, 15:58 UTC

Ergebnisse

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11. Juli 2025, 15:57 UTC

Ergebnisse

BASF 2Q EBIT Before Special Items EUR810M

11. Juli 2025, 15:54 UTC

Ergebnisse

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

11. Juli 2025, 15:54 UTC

Ergebnisse

BASF 2Q Sales Fell 2.1% on Year

11. Juli 2025, 15:53 UTC

Ergebnisse

BASF 2Q Sales EUR15.77B

11. Juli 2025, 15:52 UTC

Ergebnisse

BASF: This Was in Line With Consensus Estimates

11. Juli 2025, 15:52 UTC

Ergebnisse

BASF 2Q Ebitda Before Special Items EUR1.77B

11. Juli 2025, 15:49 UTC

Ergebnisse

BASF Reports Preliminary 2Q Figures, Adjusts 2025 Outlook

11. Juli 2025, 15:41 UTC

Market Talk

Oil, Gas Prices Not Seen Supporting Drilling Boom -- Market Talk

Peer-Vergleich

Kursveränderung

REVOLUTION Medicines Inc Prognose

Kursziel

By TipRanks

84.1% Vorteil

12-Monats-Prognose

Durchschnitt 70.88 USD  84.1%

Hoch 80 USD

Tief 57 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für REVOLUTION Medicines Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

9 ratings

9

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

40.67 / 41.96Unterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

174 / 376 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.